PIM2 and chronic myelogenous leukemia, BCR-ABL1 positive: While imatinib mesylate was effective in treating CML stem cells with high Pim-2 expression induced through STAT5; imatinib mesylate resistant cells continued to exist due to activation of Pim-2 through an alternative, STAT4 dependent pathway [185].